BRAINSTORM CELL THERAPEUTICS INC. Lessee, Operating Lease, Liability, to be Paid, Year Four
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) had Lessee, Operating Lease, Liability, to be Paid, Year Four of $179.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour · last filed 2023-11-14
- 2023-09-30: Lessee, Operating Lease, Liability, to be Paid, Year Four $179.00K.
- 2023-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Four $185.00K.
- 2023-03-31: Lessee, Operating Lease, Liability, to be Paid, Year Four $189.00K.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Four $194.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Four |
|---|---|
| 2023-09-30 | $179.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $185.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $189.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $194.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $193.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $196.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $216.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $1.33M 10-K · filed 2022-03-28 |
| 2021-09-30 | $229.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $567.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $887.00K 10-Q · filed 2021-04-26 |
| 2020-12-31 | $1.41M 10-K · filed 2021-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |